James Abbey, Ph.D.
International Strategic Collaboration Adviser
|Ph.D.||University of Wales, Swansea, Wales, UK (Nanotechnology)|
|MBA||University of Wales, Swansea, Wales, UK|
|B.S.||University of North Texas, Denton, Texas, USA (Human Resource Management)|
Dr. James Abbey is the international collaborations adviser and director of the Texas/UK Collaborative & International Collaboration at Swansea University in Wales, United Kingdom. In his role at Swansea University, Dr. Abbey helped establish the Center for NanoHealth at Swansea University. He is also one of the driving forces behind the Texas/UK Collaborative & International Collaboration, which involves a consortium of partnering institutions across the United Kingdom and Texas.
The Texas-United Kingdom Collaborative harnesses the collective experience and ambition of 10 universities and medical colleges in Texas and eight of the UK's top universities. Dr. Abbey also spearheaded the establishment of a joint Ph.D. training program between the Methodist Academy and Swansea University. This formal affiliation agreement will bring Ph.D. students to The Methodist Hospital Research Institute for translational research training. As an Affiliate Assistant Member of the Research Institute, Dr. Abbey facilitates the collaboration of investigators at Swansea University and Methodist, and is also responsible for the oversight of the joint predoctoral training program.
Dr. Abbey’s research interest are in collaborative medical discoveries and translation in the areas of biologics, nanotechnology, and chemistry; involvement in the research of open innovation systems and the affect of collaboration on the development of novel therapeutics; and design of a best-in-class, flexible, biopharmaceutical research, development, training, and production facility focused on hybrid and disposable technologies and equipment for rapid development and production of biopharmaceutical products.
Dr. Abbey’s research goal is to provide rapid, cost-effective, FDA-EMEA-MHRA-compliant, and scalable manufacturing facilities to enable an array of new products to enter both in vitro and in vivo clinical trials.
Nanotechnology, biologics, chemistry, therapeutics, preclinical studies
Ferrati S, Shamsudeen S, Summers HD, Rees P, Abbey JV, Schmulen J, Liu X, Wong ST, Bean AJ, Ferrari M, Serda RE. Inter-endothelial transport of microvectors using cellular shuttles and tunneling nanotubes. Small. 2012 Oct 22;8(20):3151-60. PMID: 22930522
Abbey JV, Davies GH, Mainwaring L. Vorsprung durch Technium: Towards a system of Innovation in South-west Wales. Regional Studies, Vol. 42.2, pp. 281 – 293, March 2008. DOI:10.1080/00343400601147281